Prurigo Nodularis Treatment Market Report 2026

The prurigo nodularis treatment market size has grown strongly in recent years. It will grow from $1.72 billion in 2025 to $1.81 billion in 2026 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing awareness of chronic inflammatory skin disorders, rising diagnosis rates of prurigo nodularis, wider availability of dermatology specialty clinics, increased use of topical corticosteroids, growing physician focus on itch management.

The prurigo nodularis treatment market size is expected to see steady growth in the next few years. It will grow to $2.2 billion in 2030 at a compound annual growth rate (CAGR) of 5%. The growth in the forecast period can be attributed to increasing approvals of novel biologics, rising investments in dermatology R&D, expanding use of precision medicine approaches, growing demand for long-term symptom control, increasing adoption of advanced laser-based therapies. Major trends in the forecast period include increasing adoption of biologic therapies, rising focus on targeted anti-inflammatory treatments, growing use of combination therapy approaches, expansion of advanced phototherapy techniques, enhanced emphasis on patient-centric treatment protocols.

The increasing incidence of chronic skin conditions is expected to drive the growth of the prurigo nodularis treatment market in the coming years. Chronic skin conditions are long-lasting or recurring disorders that often require continuous management and can significantly impact quality of life. The rise in chronic skin conditions is largely attributed to increased exposure to environmental pollutants, which can compromise the skin’s natural barrier and trigger prolonged inflammatory responses. Treatments for prurigo nodularis address the underlying causes of these chronic conditions by targeting inflammatory pathways responsible for persistent itching and skin lesions. By modulating excessive immune activity, these therapies help relieve symptoms and improve the overall quality of life for patients with chronic prurigo nodularis. For instance, in July 2023, according to the Office of Health Economics, a UK-based registered charity, hidradenitis suppurativa, a painful chronic skin condition, affects at least 200,000 people in the UK, with its economic burden estimated at approximately £3.83 ($4.35) billion per year. Therefore, the growing prevalence of chronic skin conditions is contributing to the expansion of the prurigo nodularis treatment market.

Major companies operating in the prurigo nodularis treatment market are concentrating on the development of advanced therapies, such as monoclonal antibodies, that target specific immune pathways to deliver more effective symptom relief. Monoclonal antibodies are laboratory-engineered molecules designed to replicate the immune system’s ability to combat harmful agents. For example, in August 2024, Galderma, a Switzerland-based pharmaceutical company, announced that the US Food and Drug Administration approved Nemluvio (nemolizumab) for the treatment of adult patients with prurigo nodularis. This approval was supported by positive outcomes from the OLYMPIA clinical trials, in which Nemluvio showed significant reductions in itch severity and skin nodules. The therapy works by specifically targeting IL-31 signaling, a key driver of prurigo nodularis symptoms.

In November 2025, Sanofi S.A., a France-based biopharmaceutical company active in prurigo nodularis treatment, partnered with Regeneron Pharmaceuticals Inc. to advance the development of the biologic therapy Dupixent, which met all primary and secondary endpoints in a pivotal study for allergic fungal rhinosinusitis. This collaboration is intended to accelerate therapeutic innovation by combining complementary scientific expertise and advanced biologic development capabilities. Regeneron Pharmaceuticals Inc. is a US-based biotechnology company.

Major companies operating in the prurigo nodularis treatment market are Roche Holding AG, Sanofi S.A., Amgen Inc., Regeneron Pharmaceuticals Inc., Galderma S.A, Incyte Corporation, LEO Pharma A/S, Almirall S.A., Maruho Co. Ltd., VYNE Therapeutics Inc., Kiniksa Pharmaceuticals Ltd., Trevi Therapeutics Inc., Keymed Biosciences Inc., Shanghai SIGMA High-tech Co. Ltd., Celgene Corporation, Celldex Therapeutics Inc., Pfizer Inc., Eli Lilly And Company, AbbVie Inc., Johnson And Johnson, Bristol Myers Squibb, Novartis AG, AstraZeneca PLC.

North America was the largest region in the prurigo nodularis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the prurigo nodularis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the prurigo nodularis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the prurigo nodularis treatment market by increasing costs of imported active pharmaceutical ingredients, biologic drug substances, phototherapy equipment, and laser devices used in advanced treatment settings. Hospitals and specialty dermatology clinics in North America and Europe are most affected due to reliance on imported biologics and medical devices, while Asia-Pacific faces higher production costs for export-oriented pharmaceutical manufacturing. These tariffs are contributing to higher treatment costs and slower adoption of premium therapies. However, they are also encouraging domestic drug manufacturing, regional clinical research investments, and localized production of dermatology treatment equipment.

The prurigo nodularis treatment market research report is one of a series of new reports that provides prurigo nodularis treatment market statistics, including prurigo nodularis treatment industry global market size, regional shares, competitors with a prurigo nodularis treatment market share, detailed prurigo nodularis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the prurigo nodularis treatment industry. This prurigo nodularis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Prurigo nodularis treatment includes a range of medical interventions aimed at relieving persistent itching and managing the skin lesions associated with this inflammatory condition. The primary goal of treatment is to break the itch-scratch cycle that worsens symptoms. These therapies focus on reducing itch intensity, promoting the healing of nodules, and improving overall patient quality of life.

The main treatment types for prurigo nodularis include medications, cryotherapy, phototherapy, pulsed dye laser therapy, and other approaches. Medications are used to decrease itching, reduce inflammation, and regulate immune responses. Diagnosis is typically performed using methods such as skin biopsy, blood tests, and other evaluations. Treatments are administered through various routes, including topical, oral, and parenteral administration. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, and treatments are utilized by end users such as clinics, hospitals, and other healthcare settings.

The prurigo nodularis treatment market consists of revenues earned by entities by providing services such as medical consultation, psychological support, wound care, and bandaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The prurigo nodularis treatment market also includes sales of patch test kits, punch biopsy tools, and injectable monoclonal antibodies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.